Evidence map›Paper›PMID 41674663›Full record

ArticleGenes & diseases2026

Targeting MDK alleviates bone loss via dual regulation of osteogenic differentiation and inflammatory cytokine expression.

Xieyidai Ruze, Yutong Hu, Xiongyi Wang, Houfu Lai, Ruizhi Zhang, Sheng Pan, Jiajun Zhang, Yike Wang, Simin Yun, Ying Xu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xieyidai RuzeDepartment of Orthopedics, Department of Osteoporosis, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, China.
Yutong HuDepartment of Orthopedics, Department of Osteoporosis, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, China.
Xiongyi WangDepartment of Orthopedics, Department of Osteoporosis, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, China.
Houfu LaiDepartment of Orthopedics, Department of Osteoporosis, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, China.
Ruizhi ZhangDepartment of Orthopedics, Department of Osteoporosis, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, China.
Sheng PanDepartment of Orthopedics, Department of Osteoporosis, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, China.
Jiajun ZhangDepartment of Orthopedics, Department of Osteoporosis, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, China.
Yike WangDepartment of Orthopedics, Department of Osteoporosis, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, China.
Simin YunDepartment of Orthopedics, Department of Osteoporosis, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, China.
Ying XuJiangsu Key Laboratory of Neuropsychiatric Diseases and Cambridge-Su Genomic Resource Center, Medical College of Soochow University, Suzhou, Jiangsu 215000, China.
Junjie LiDepartment of Orthopedics, Department of Osteoporosis, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, China.
Youjia XuDepartment of Orthopedics, Department of Osteoporosis, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Growth factors are bioactive molecules that play crucial roles in regulating growth, development, and disease processes, both locally and systemically. Identifying growth factors involved in bone homeostasis and targeting them is a key strategy for treating bone metabolic diseases. In this study, we observed significantly elevated serum levels of midkine (MDK) in patients with postmenopausal osteoporosis and in ovariectomized mice, based on clinical data and animal experiments. We also identified a negative correlation between MDK levels and bone mineral density. The small molecule inhibitor of MDK, iMDK, effectively mitigated estrogen deficiency-induced bone loss by promoting bone formation and inhibiting inflammatory factors. Our

Indexed as

Growth factorsInflammatorycytokinesMDKOsteoblastTargeted therapy

Identifiers

PMID41674663
PMCPMC12886531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.